Therapeutic vaccination of chronic hepatitis B patients with virus suppression by antiviral therapy: A randomized, controlled study of co-administration of HBsAg/AS02 candidate vaccine and lamivudine

Vaccine

Volumn 25, Issue 51, 2007, Pages 8585-8597

  Vandepapelière, Pierre ^j   Lau, George K K ^a   Leroux Roels, Geert ^b   Horsmans, Yves ^c   Gane, Edward ^d   Tawandee, Tawesak ^e   Merican, Mohd Ismail bin ^f   Win, Khin Maung ^g   Trepo, Christian ^h   Cooksley, Graham ⁱ   Wettendorff, Martine ^j   Ferrari, Carlo ^k  

^a QUEEN MARY HOSPITAL   (Hong Kong)

^b GHENT UNIVERSITY   (Belgium)

^c CLINIQUES UNIVERSITAIRES SAINT LUC   (Belgium)

^d MIDDLEMORE HOSPITAL   (New Zealand)

^e MAHIDOL UNIVERSITY   (Thailand)

^f HOSPITAL KUALA LUMPUR   (Malaysia)

^g Yangon General Hospital   (Myanmar)

^h HÔTEL DIEU   (France)

ⁱ UNIVERSITY OF QUEENSLAND   (Australia)

^j GLAXOSMITHKLINE BIOLOGICALS   (Belgium)

^k UNIVERSITY OF PARMA   (Italy)

more..

Author keywords

Adjuvant; Chronic hepatitis B; Therapeutic vaccine

Indexed keywords

AS02B ADJUVANT; HEPATITIS B SURFACE ANTIGEN; HEPATITIS B VACCINE; HEPATITIS B(E) ANTIBODY; HEPATITIS B(E) ANTIGEN; IMMUNOLOGICAL ADJUVANT; LAMIVUDINE; UNCLASSIFIED DRUG;

ADULT; ARTICLE; CLINICAL TRIAL; COMBINATION CHEMOTHERAPY; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CYTOKINE PRODUCTION; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; FEMALE; FLU LIKE SYNDROME; HEPATITIS B; HUMAN; JAUNDICE; LYMPHOCYTE PROLIFERATION; MAJOR CLINICAL STUDY; MALE; MONOTHERAPY; MULTICENTER STUDY; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RASH; RESPIRATORY TRACT DISEASE; SEROCONVERSION; STATISTICAL SIGNIFICANCE; TREATMENT OUTCOME; VIRUS LOAD;

ADJUVANTS, IMMUNOLOGIC; ADOLESCENT; ADULT; ANTIBODIES, VIRAL; ANTIVIRAL AGENTS; COMBINED MODALITY THERAPY; FEMALE; HEPATITIS B SURFACE ANTIGENS; HEPATITIS B VACCINES; HEPATITIS B, CHRONIC; HUMANS; IMMUNITY, CELLULAR; IMMUNOTHERAPY; LAMIVUDINE; MALE; MIDDLE AGED; REVERSE TRANSCRIPTASE INHIBITORS; TREATMENT OUTCOME;

EID: 36549028324     PISSN: 0264410X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.vaccine.2007.09.072     Document Type: Article

References (64)

1. Lok A.S.F. Chronic hepatitis B. NEJM 346 22 (2002) 1682-1683
2. World Health Organization. Hepatitis B World Health Organization fact sheet no. 204. Available at: http://www.who.int/mediacentre/factsheets/fs204/en/index.html.
3. Beasley R.P. Hepatitis B virus. The major etiology of hepatocellular carcinoma. Cancer 61 (1988) 1942-1956
4. Lavanchy D. Hepatitis B virus epidemiology, disease burden, treatment, and current and emerging prevention and control measures. J Viral Hepat 11 (2004) 97-107
5. Wright T.L. Introduction to chronic hepatitis B infection. Am J Gastroenterol 101 (2006) S1-S6
6. Hoofnagle J.H., Doo E., Liang T.J., Fleischer R., and Lok A.S.F. Management of hepatitsB: summary of a clinical research workshop. Hepatology 45 (2007) 1056-1075
7. Gish R. Clinical trial results of new therapies for HBV: implications for treatment guidelines. Semin Liver Dis 25 S1 (2005) 29-39
8. Lok A.S.F. The maze of treatments for hepatitis B. NEJM 352 26 (2005) 2743-2746
9. Millich D.R. Pathobiology of acute and chronic hepatitis B virus infection: an introduction. J Viral Hepat 4 (1997) 25-30
10. Chisari F.V., and Ferrari C. Hepatitis B virus immunopathogenesis. Ann Rev Immunol 13 (1995) 29-60
11. Vandepapeliere P. Therapeutic vaccination for treatment of chronic hepatitis B: rationale, review and prospects for future development. Viral Hep Rev 6 (2000) 65-92
12. Ferrari C., Penna A., Bertoletti A., Valli A., Antoni A.D., Giuberti T., et al. Cellular immune response to hepatitis B virus-encoded antigens in acute and chronic hepatitis B virus infection. J Immunol 145 (1990) 3442-3449
13. Jung M., Hartmann B., Gerlach J., Diepolder H., Gruber R., Schraut W., et al. Virus-specific lymphokine production differs quantitatively but not qualitatively in acute and chronic hepatitis B infection. Virology 261 (1999) 165-172
14. Lok A.S.F., Lai C.L., Wu P.C., Leung E.K., and Lam T.S. Spontaneous hepatitis B antigen to antibody seroconversion and reversion in Chinese patients with chronic hepatitis B virus infection. Gastroenterology 92 (1987) 1839-1843
15. Evans A.A., Fine M., and London W.T. Spontaneous seroconversion in hepatitis B e antigen-positive chronic hepatitis B: implications for interferon therapy. J Infect Dis 176 (1997) 845-850
16. Liaw Y.F., and Tsai S.L. Pathogenesis and clinical significance of spontaneous exacerbations and remissions in chronic hepatitis B virus infection. Viral Hep Rev 3 3 (1997) 143-154
17. Lau G.K.K., Liang R., Lee C.K., Yuen S.T., Hou J., Lim W.L., et al. Clearance of persistent hepatitis B virus infection in Chinese bone marrow transplant recipients whose donors were anti-hepatitis B core and anti-hepatitis B surface antibody positive. J Infect Dis 178 (1998) 1585-1591
18. Jung M.C., Diepolder H.M., Spengler U., Wierenga E.A., Zachoval R., Hoffman R.M., et al. Activation of heterogeneous hepatitis B (HB) core and e antigen-specific CD4+ T-cell population during seroconversion to anti-HBe and anti-HBs in hepatitis B virus infection. J Virol 69 6 (1995) 3358-3368
19. Jung M., Spengler U., Schraut W., Hoffman R., Zachoval R., Eisemburg J., et al. Hepatitis B virus antigen-specific T-cell activation in patients with acute and chronic hepatitis B. J Hepatol 13 (1991) 310-317
20. Penna A., Chisari F.V., Bertoletti A., Missale G., Fowler P., Giuberti T., et al. Cytotoxic T lymphocytes recognize an HLA-A2-restricted epitope within the hepatitis B virus nucleocapsid antigen. J Exp Med 174 (1991) 1565-1570
21. Rehermann B., Fowler P., Sidney J., Person J., Redeker A., Brown M., et al. The cytotoxic T lymphocyte response to multiple hepatitis B virus polymerase epitopes during and after acute viral hepatitis. J Exp Med 181 (1995) 0147-0158
22. Thimme R., Wieland S., Steiger C., Ghrayeb J., Reimann K.A., Purcell R.H., et al. CD8+ T cells mediate viral clearance and disease pathogenesis during acute hepatitis B virus infection. J Virol 77 (2003) 68-76
23. Sing G.K., Ladhams A., Arnold S., Parmar H., Chen X., Cooper J., et al. A longitudinal analysis of cytotoxic T lymphocyte precursor frequencies to the hepatitis B virus in chronically infected patients. J Viral Hepat 8 (2001) 19-29
24. Webster G.J.M., Reignat S., Brown D., Ogg G.S., Jones L., Seneviratne S.L., et al. Longitudinal analysis of CD8+T cells specific for structural and nonstructural hepatitis B virus proteins in patients with chronic hepatitis B: implications for immunotherapy. J Virol 78 11 (2004) 5707-5719
25. Webster G.J.M., and Bertoletti A. Quantity and quality of virus specific CD8 cell response: relevance to the design of a therapeutic vaccine for chronic HBV infection. Mol Immunol 38 (2001) 467-473
26. Boni C., Bertoletti A., Penn A., Cavalli A., Pilli M., Urbani S., et al. Lamivudine treatment can restore T-cell responsiveness in chronic hepatitis B. J Clin Invest 102 5 (1998) 1-8
27. Le Guerhier F., Thermet A., Guerret S., Chevallier M., Jamard C., Gibbs C.S., et al. Antiviral effect of adefovir in combination with a DNA vaccine in the duck hepatitis B virus infection model. J Hepatol 38 (2003) 328-334
28. Menne S., Roneker C.A., Korba B.E., Gerin J.L., Tennant B.C., and Cote P.J. Immunization with surface antigens alone and after treatment with 1-(2-fluoro-5-methyl-beta-l-arabinofuranosyl)-uracil (L-FMAU) breaks humoral and cell-mediated immune tolerance in chronic woodchuck hepatitis virus infection. J Virol 76 (2002) 5305-5314
29. Lalvani A., Moris P., Voss G., Pathan A.A., Kester K.E., Brookes R., et al. Potent induction of focused Th1-type cellular and humoral immune responses by RTSS/SBAS2, a recombinant plasmodium flasiparum malaria vaccine. J Infect Dis 180 (1999) 1656-1664
30. Bertoletti A., and Naoumov N.V. Translation of immunological knowledge into better treatments of chronic hepatitis B. J Hepatol 39 (2003) 115-124
31. Carman W.F., Tucker T., Song E., Hawarden D., Kirsch R.E., Van Deursen F.R., et al. Efficacy of a third generation preS1/preS2 containing HBV carrier (Hepagene) as immunotherapy for HBeAg positive chronic hepatitis. J Hepatol 34 (2001) 917-921
32. Pol S., Nalpas B., Driss F., Michel M.-L., Tiollais P., Denis J., et al. Efficacy and limitations of a specific immunotherapy in chronic hepatitis B. J Hepatol 34 (2001) 917-921
33. Vandepapeliere P., Rehermann B., Koutsoukos M., Moris P., Garcon N., Wettendorf M., et al. Potent enhancement of cellular and humoral immune responses against recombinant hepatitis B antigens using AS02A adjuvant in healthy adults. Vaccine 23 (2005) 2591-2601
34. Boni C., Penna A., Bertoletti A., Lamonaca V., Rapti I., Missale G., et al. Transient restoration of anti-viral T cell responses induced by lamivudine therapy in chronic hepatitis B. J Hepatol 39 (2003) 595-605
35. Jung M.-C., Grüner N., Zachoval R., Schraut W., Gerlach T., Piepolder H., et al. Immunological monitoring during therapeutic vaccination as a prerequisite for the design of new effective therapies: induction of a vaccine-specific CD4+ T cell proliferative response in chronic hepatitis B carriers. Vaccine 20 (2002) 3596-3612
36. Dahmen A., Herzogg-Hauff S., Böcher W.O., Galle P.R., and Löhr H.F. Clinical and immunological efficacy of intradermal vaccine plus lamivudine with or without interleukin-2 in patients with chronic hepatitis B. J Med Virol 66 (2002) 452-460
37. Couillin I., Pol S., Mancini M., Driss F., Bréchot C., Tiollais P., et al. Specific vaccine therapy in chronic hepatitis B: induction of T cell proliferative responses specific for envelope antigens. J Infect Dis 180 (1999) 15-26
38. Mancini-Bourgine M., Fontaine H., Scott-Algara D., Pol S., Brechot C., and Michel M.L. Induction or expansion of T-cell responses by a hepatitis B DNA vaccine administered to chronic HBV carriers. Hepatology 40 (2004) 874-882
39. Bienzle U., Günther M., Neuhaus R., Vandepapeliere P., Vollmar J., Lun A., et al. Immunization with an adjuvant hepatitis B vaccine after liver transplantation for hepatitis B related disease. Hepatology 38 (2003) 811-819
40. Nevens F., Roskams T., Van Vlierbergehe H., Horsmans Y., Sprengers D., Elewaut A., et al. A pilot study of therapeutic vaccination with envelope protein E1 in 35 patients with chronic hepatitis C. Hepatology 38 (2003) 1289-1296
41. Guidotti L.G., Ishikawa T., Hobbs M.V., Matzke B., Schrieiber R., and Chrisari F.V. Intracellular inactivation of the hepatitis B virus by cytotoxic T lymphocytes. Immunity 4 (1996) 25-36
42. Penna A., Fowler P., Bertoletti A., Guilhot S., Moss B., Margolskee R.F., et al. Hepatitis B virus (HBV)-specific cytotoxic T-cell (CTL) response in humans: characterization of HLA class II-restricted CTLs that recognize endogenously synthesized HBV envelope antigens. J Virol 66 2 (1992) 1193-1196
43. Nayersina R., Fowler P., Guilhot S., Missale G., Cerny A., Schlicht H.-J., et al. HLA-A2 restricted cytotoxic T-lymphocyte responses to multiple hepatitis B surface antigen epitopes during hepatitis B virus infection. J Immunol 150 (1993) 4659-4671
44. Alberti A., Diana S., Sculard G.H., Eddleston A.L., and Williams R. Detection of a new antibody system reacting with Dane particles in hepatitis B virus infection. Br Med J 138 (1978) 625-638
45. Maruyama T., McLachlan A., Lino S., Koike K., Kurokawa K., and Millich D. The serology of chronic hepatitis B infection revisited. J Clin Invest 91 (1993) 2586-2595
46. Nagaraju K., Naik S.R., and Naik S. Functional implications of hepatitis B surface antigen (HBsAg) in the T cells of chronic HBV carriers. J Viral Hepat 4 (1997) 221-230
47. Jones C.D., Page M., Bacon A., Cahill E., Bentley M., et al. T-cell and antibody response characterisation of a new recombinant pre-S1, pre-S2 and SHBs antigen-containing hepatitis B vaccine; demonstration of superior anti-SHBs antibody induction in responder mice. Vaccine 17 20-21 (1999) 2528-2537
48. Desombere I., Willems A., Gijbels Y., and Leroux-Roels G. Partial delipidation improves the T cell antigenicity of hepatitis B surface antigen. J Virol 80 (2006) 3506-3514
49. Rahman F., Dahmen A., Herzog-Hauff S., Böcher W.O., Galle P.R., and Löhr H.F. Cellular and humoral immune responses induced by intradermal or intramuscular vaccination with the major hepatitis B surface antigen. Hepatology 31 2 (2000) 521-527
50. Horiike N., Akbar F., Michitaka K., Joukou K., Yamamoto K., Kojima N., et al. In vivo immunization by vaccine therapy following virus suppression by lamivudine: a novel approach for treating patients with chronic hepatitis B. J Clin Virol 32 (2005) 156-161
51. Zhou D., and Ertl H.C.J. Therapeutic potential of adenovirus as a vaccine vector for chronic virus infections. Expert Opin Biol Ther 6 (2006) 63-72
52. Davis H.L. DNA vaccines for prophylactic or therapeutic immunization against hepatitis B virus. MT Sinai J Med 66 2 (1999) 84-90
53. Michel M.-L., Davis H.L., Schleef M., Mancini M., Tiollais P., and Whalen R.G. DNA-mediated immunization to hepatitis B surface antigen in mice: aspects of the humoral response mimic hepatitis B viral infection in humans. Proc Natl Acad Sci USA 92 (1995) 530711
54. Aguilar J.C., Lobaina Y., Muzio V., Garcia D., Penton E., and Iglesis E. Development of a nasal vaccine for chronic hepatitis B infection that uses the ability of hepatitis B core antigen to stimulate a strong Th1 response against hepatitis B surface antigen. Immunol Biol 82 (2004) 539-546
55. Ferrari C., Bertoletti A., Penna A., Cavalli A., Valli A., Missale G., et al. Identification of immunodominant T cell epitopes of the hepatitis B virus nucleocapsid antigen. J Clin Invest 88 (1991) 214-222
56. Marinos G., Torre F., Chokshi S., Hussain M., Clarke B.E., Rowlands D.J., et al. Induction of T-helper cell response to hepatitis B core antigen in chronic hepatitis B: a major factor in activation of the host immune response to the hepatitis B virus. Hepatology 22 (1995) 1040-1049
57. Tsai S.L., Cheno P.J., Lai M.Y., Yang P.M., Sung J.L., Huang J.H., et al. Acute exacerbations of chronic type B hepatitis are accompanied by increased T cell responses to hepatitis B core and e antigens. J Clin Invest 89 (1992) 87-96
58. Lau G.K.K., Suri D., Liang R., Rigopoulou E.I., Thomas M.G., Mullerova I., et al. Resolution of chronic hepatitis B and anti-HBs seroconversion in humans by adoptive transfer of immunity to hepatitis B core antigen. Gastroenterology 122 (2002) 614-624
59. Milich D.R. Influence of T-helper cell subsets and crossregulation in hepatitis B virus infection. J Viral Hepat 4 Suppl. 2 (1997) 48-59
60. Milich D.R., Chen M.K., Hughes J.L., and Jones J.E. The secreted hepatitis B precore antigen can modulate the immune response to the nucleocapsid: a mechanism for persistence. J Immunol 160 4 (1998) 2013-2021
61. Milich D.R., Schödel F., Hughes J.L., Jones J.E., and Peterson D.L. The hepatitis B virus core and e antigens elicit different Th cell subsets: antigen structure can affect Th cell phenotype. J Virol 71 3 (1997) 2192-2201
62. Heathcote J., McHutchison J., Lee S., Tong M., Benner K., Minuk G., et al. A pilot study of the CY-1899-T-cell vaccine in subjects chronically infected with hepatitis B virus. Hepatology 30 2 (1999) 531-536
63. Sallberg M., Hughes J., Javadian A., Ronlov G., Hultgren C., Townsend K., et al. Genetic immunization of chimpanzees chronically infected with the hepatitis B virus, using a recombinant retroviral vector encoding the hepatitis B virus core antigen. Hum Gene Ther 9 12 (1998) 1719-1729
64. Yang S.H., Lee C.G., Im S.J., Kim Y.M., Son J.M., et al. Correlation of antiviral T-cell responses with suppression of viral rebound in chronic hepatitis B carriers: a proof-of-concept study. Gene Ther 13 (2006) 1110-1117